Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis

View More View Less
  • 1 Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; and
  • 2 Yale University School of Medicine, New Haven, Connecticut.
Restricted access

Background: The cost of cancer treatment has increased significantly in recent decades, but it is unclear whether these costs have been associated with commensurate improvement in clinical value. This study aimed to assess the association between the cost of cancer treatment and 4 of the 5 NCCN Evidence Blocks (EB) measures of clinical value: efficacy of regimen/agent, safety of regimen/agent, quality of evidence, and consistency of evidence. Methods: This is a cross-sectional, observational study. We obtained NCCN EB ratings for all recommended, first-line, and/or maintenance treatments for the 30 most prevalent cancers in the United States and calculated direct pharmacologic treatment costs (drug acquisition, administration fees, guideline-concordant supportive care medications) using Medicare reimbursement rates in January 2019. We used generalized estimating equations to estimate the association between NCCN EB measures and treatment cost with clustering at the level of the treatment indication. Results: A total of 1,386 treatments were included. Among time-unlimited treatments (those administered on an ongoing basis without a predetermined stopping point), monthly cost was positively associated with efficacy ($3,036; 95% CI, $1,782 to $4,289) and quality of evidence ($1,509; 95% CI, $171 to $2,847) but negatively associated with safety (–$1,470; 95% CI, –$2,790 to –$151) and consistency of evidence (–$2,003; 95% CI, –$3,420 to –$586). Among time-limited treatments (those administered for a predetermined interval or number of cycles), no NCCN EB measure was significantly associated with treatment cost. Conclusions: An association between NCCN EB measures and treatment cost was inconsistent, and the magnitude of the association was small compared with the degree of cost variation among treatments with the same EB scores. The clinical value of cancer treatments does not seem to be a primary determinant of treatment cost.

Submitted December 21, 2019; accepted for publication April 6, 2020.

Author contributions: Study concept and design: All authors. Dataset creation: Mitchell, Tabatabai, Dey, Ohn. Data analysis: Mitchell, Curry. Results presentation: Mitchell, Tabatabai, Dey, Bach. Approval of final manuscript: All authors.

Disclosures: Dr. Mitchell has disclosed that he received a research award from Conquer Cancer Foundation, partially funded by Merck. Dr. Bach has disclosed that he has received personal fees from WebMD, Defined Health, JMP Securities, Mercer, Foundation Medicine, Grail, Morgan Stanley, Oppenheimer & Co, Cello Health, Oncology Analytics, Anthem, Magellan Health, America’s Health Insurance Plans, and EQRx; grants from Kaiser Permanente and Arnold Ventures; nonfinancial support from Oppenheimer & Co, America’s Health Insurance Plans, and Oncology Analytics; and other from Oncology Analytics. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: Aaron P. Mitchell, MD, MPH, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY 10017. Email: mitchea2@mskcc.org

Supplementary Materials

    • Supplemental Materials (PDF 531.49 KB)
  • 1.

    Bach P. Monthly and median costs of cancer drugs at the time of FDA approval 1965-2015. Memorial Sloan Kettering Cancer Center. Accessed December 9, 2015. Available at: https://www.mskcc.org/research-areas/programs-centers/health-policy-outcomes/cost-drugs

  • 2.

    Dusetzina SB, Huskamp HA, Keating NL. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019. JAMA 2019;321:20252028.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Alevizakos M, Gaitanidis A, Appleman L. Quantification of the financial burden of antineoplastic agent price increases [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 6519.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst 2015;108:djv370.

  • 5.

    Howard DH, Bach PB, Berndt ER, . Pricing in the market for anticancer drugs. J Econ Perspect 2015;29:139162.

  • 6.

    Barnes TA, Amir E, Templeton AJ, . Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev 2017;56:17.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Amir E, Seruga B, Martinez-Lopez J, . Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011;29:25432549.

  • 8.

    Mailankody S, Prasad V. Implications of proposed Medicare reforms to counteract high cancer drug prices. JAMA 2016;316:271272.

  • 9.

    Saluja R, Arciero VS, Cheng S, . Examining trends in cost and clinical benefit of novel anticancer drugs over time. J Oncol Pract 2018;14:e280294.

  • 10.

    Becker DJ, Lin D, Lee S, . Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs. J Oncol Pract 2017;13:e653665.

  • 11.

    Vivot A, Jacot J, Zeitoun JD, . Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015. Ann Oncol 2017;28:11111116.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Del Paggio JC, Sullivan R, Schrag D, . Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 2017;18:887894.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 2015;1:539540.

  • 14.

    Soriot P. Statement of Pascal Soriot, chief executive officer, AstraZeneca, before the Committee on Finance, United States Senate, concerning drug pricing in America: a prescription for change, part II. Accessed September 27, 2019. Available at: https://www.finance.senate.gov/imo/media/doc/26FEB2019SORIOT-ASTRAZENECA.pdf

  • 15.

    Harris G. Cost of developing new medicine swelled to $802 million, research study reports. The Wall Street Journal. December 3, 2001. Accessed September 27, 2019. Available at: https://www.wsj.com/articles/SB1007336440403996240

  • 16.

    Burkholder R. Pricing and value of cancer drugs. JAMA Oncol 2015;1:841842.

  • 17.

    Carlson RW, Jonasch E. NCCN Evidence Blocks. J Natl Compr Canc Netw 2016;14(5 Suppl):616619.

  • 18.

    Shah-Manek B, Wong W, Ravelo A, . Oncologists’ perceptions of drug affordability using NCCN Evidence Blocks: results from a national survey. J Manag Care Spec Pharm 2018;24:565571.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626633.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 607 607 607
PDF Downloads 102 102 102
EPUB Downloads 0 0 0